scholarly journals Editorial: Computational Genomics and Molecular Medicine for Emerging COVID-19

2021 ◽  
Vol 18 (4) ◽  
pp. 1227-1229
Author(s):  
Dong-Qing Wei ◽  
Aman Chandra Kaushik ◽  
Gurudeeban Selvaraj ◽  
Yi Pan
Keyword(s):  
Computational Genomics ◽  
Molecular Medicine

Clinical Science in the 1990s

1990 ◽  
Vol 78 (1) ◽  
pp. 1-1
Author(s):  
M. J. Brown
Keyword(s):  
Medical Research ◽  
Review Process ◽  
Molecular Level ◽  
Short Interval ◽  
Clinical Science ◽  
Molecular Medicine ◽  
Mutual Benefit ◽  
Real Progress ◽  
General Journal

From this issue, Clinical Science will increase its page numbers from an average of 112 to 128 per monthly issue. This welcome change — equivalent to at least two manuscripts — has been ‘forced’ on us by the increasing pressure on space; this has led to an undesirable increase in the delay between acceptance and publication, and to a fall in the proportion of submitted manuscripts we have been able to accept. The change in page numbers will instead permit us now to return to our exceptionally short interval between acceptance and publication of 3–4 months; and at the same time we shall be able not only to accept (as now) those papers requiring little or no revision, but also to offer hope to some of those papers which have raised our interest but come to grief in review because of a major but remediable problem. Our view, doubtless unoriginal, has been that the review process, which is unusually thorough for Clinical Science, involving a specialist editor and two external referees, is most constructive when it helps the evolution of a good paper from an interesting piece of research. Traditionally, the papers in Clinical Science have represented some areas of research more than others. However, this has reflected entirely the pattern of papers submitted to us, rather than any selective interest of the Editorial Board, which numbers up to 35 scientists covering most areas of medical research. Arguably, after the explosion during the last decade of specialist journals, the general journal can look forward to a renaissance in the 1990s, as scientists in apparently different specialities discover that they are interested in the same substances, asking similar questions and developing techniques of mutual benefit to answer these questions. This situation arises from the trend, even among clinical scientists, to recognize the power of research based at the cellular and molecular level to achieve real progress, and at this level the concept of organ-based specialism breaks down. It is perhaps ironic that this journal, for a short while at the end of the 1970s, adopted — and then discarded — the name of Clinical Science and Molecular Medicine, since this title perfectly represents the direction in which clinical science, and therefore Clinical Science, is now progressing.

scholarly journals Genetic and epigenetic mechanisms in the development of congenital heart diseases

2021 ◽  
Vol 4 (2) ◽  
pp. e000196
Author(s):  
Yue Wu ◽  
Xiaosi Jin ◽  
Yuhao Zhang ◽  
Jing Zheng ◽  
Rulai Yang
Keyword(s):  
Congenital Heart ◽  
Heart Diseases ◽  
Gene Mutations ◽  
Morbidity And Mortality ◽  
Molecular Medicine ◽  
Epigenetic Mechanisms ◽  
Epigenetic Factors ◽  
Near Future

Congenital heart disease (CHD) is the most common of congenital cardiovascular malformations associated with birth defects, and it results in significant morbidity and mortality worldwide. The classification of CHD is still elusive owing to the complex pathogenesis of CHD. Advances in molecular medicine have revealed the genetic basis of some heart anomalies. Genes associated with CHD might be modulated by various epigenetic factors. Thus, the genetic and epigenetic factors are gradually accepted as important triggers in the pathogenesis of CHD. However, few literatures have comprehensively elaborated the genetic and epigenetic mechanisms of CHD. This review focuses on the etiology of CHD from genetics and epigenetics to discuss the role of these factors in the development of CHD. The interactions between genetic and epigenetic in the pathogenesis of CHD are also elaborated. Chromosome abnormalities and gene mutations in genetics, and DNA methylations, histone modifications and on-coding RNAs in epigenetics are summarized in detail. We hope the summative knowledge of these etiologies may be useful for improved diagnosis and further elucidation of CHD so that morbidity and mortality of children with CHD can be reduced in the near future.

Computational genomics of Torque teno sus virus and Porcine circovirus in swine samples from Canada

2021 ◽  
Vol 134 ◽  
pp. 171-180
Author(s):  
Nariman Shahhosseini ◽  
Christina Frederick ◽  
Marie-Pierre Letourneau-Montminy ◽  
Benoit-Biancamano Marie-Odile ◽  
Gary P. Kobinger ◽  
...  
Keyword(s):  
Computational Genomics ◽  
Porcine Circovirus ◽  
Torque Teno Sus Virus

scholarly journals Influence of spatial structure on protein damage susceptibility: a bioinformatics approach

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maximilian Fichtner ◽  
Stefan Schuster ◽  
Heiko Stark
Keyword(s):  
Amino Acids ◽  
Molecular Medicine ◽  
Protein Damage ◽  
Aging Research ◽  
Form And Function ◽  
The Core ◽  
And Function ◽  
Thermophilic Organisms ◽  
Damage Susceptibility ◽  
Protein Shell

AbstractAging research is a very popular field of research in which the deterioration or decline of various physiological features is studied. Here we consider the molecular level, which can also have effects on the macroscopic level. The proteinogenic amino acids differ in their susceptibilities to non-enzymatic modification. Some of these modifications can lead to protein damage and thus can affect the form and function of proteins. For this, it is important to know the distribution of amino acids between the protein shell/surface and the core. This was investigated in this study for all known structures of peptides and proteins available in the PDB. As a result, it is shown that the shell contains less susceptible amino acids than the core with the exception of thermophilic organisms. Furthermore, proteins could be classified according to their susceptibility. This can then be used in applications such as phylogeny, aging research, molecular medicine, and synthetic biology.

scholarly journals Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST

2012 ◽  
Vol 198 (4) ◽  
pp. 737-745 ◽  
Author(s):  
Mizuki Nishino ◽  
Jyothi P. Jagannathan ◽  
Katherine M. Krajewski ◽  
Kevin O’Regan ◽  
Hiroto Hatabu ◽  
...  
Keyword(s):  
Tumor Response ◽  
Response Assessment ◽  
Molecular Medicine ◽  
Response Criteria ◽  
Specific Response

scholarly journals HIV Universal Vaccine

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Marek Malecki ◽  
Bianka Saetre
Keyword(s):  
Viral Infections ◽  
Natural Infection ◽  
High Specificity ◽  
Molecular Medicine ◽  
High Efficacy ◽  
Therapeutic Vaccines ◽  
Rapid Reduction ◽  
Universal Vaccine ◽  
Healthy Donors ◽  
Induced Immunity

Background: For many deadly viruses, there are no preventive and / or therapeutic vaccines approved by health authorities World-wide (e.g., HIV, Ebola, Dengue, and many others). Although, for some viruses, prophylactic vaccines are very effective (e.g., HBV, Polio, Rota, and many others). In this realm, we design, manufacture, test, and streamline into the clinics novel viral universal vaccines (VUV). VUV have such unique features, that medical vaccination or natural infection induced immunity against some viruses (e.g., HBV) in patients, who became infected with other viruses (e.g., HIV), upon the VUV’s administration, is redirected against these other, newly infecting viruses (e.g., HIV). Specific Aim: The specific aim of this work was biomolecular engineering of the HIV universal vaccine (HIVUV) comprising the two main functional domains: CD4 or anti-gp120 - as the HIV tagging domain and HBsAg - as the immune response eliciting domain, so that upon its administration the HBV medical immunization or natural infection induced immunity would be redirected, accelerated, and amplified to fight the HIV infection. Healthy Donors and Patients: Per the Institutional Review Board approval and in compliance with the Declaration of Helsinki, all healthy donors and patients were presented with the Patients’ Bill of Rights and provided Patient Informed Consent. All the procedures were pursued by the licensed medical doctors. Methods & Results: We have biomolecularly engineered HIV universal vaccine (HIVUV) comprising human CD4 or anti-gp120 and HBsAg of HBV. By immunoblotting and magnetic activated molecular sorting, we have demonstrated high specificity of this vaccine in binding HIV. By flow cytometry and nuclear magnetic resonance, we have demonstrated high efficacy of these vaccines to engage HBV immunized patients’ immune system to work against HIV. Administration of HIVUV to blood or lymph of the HIV+ patients resulted in rapid reduction of the HIV viremia down to undetectable. It also resulted in protection of populations of CD4+ cells against HIV caused decline. Conclusions: We have demonstrated the proof of concept for high efficacy of VUV, specifically HIVUV, in annihilating HIV. Nevertheless, the same compositions, processes, and methods, for persons skilled in biotechnology, pharmacogenomics, and molecular medicine, are adaptable for other deadly viral infections, which we vigorously pursue.

Sign in / Sign up

Export Citation Format

Share Document